4/A: Greenwich LifeSciences CEO Snehal Patel Acquires 3,500 Shares
SEC Form 4/A
Greenwich LifeSciences CEO Snehal Patel purchased 3,500 shares of common stock at $12.49 per share on March 5, 2024, according to a Form 4/A filing.
Summary
- On March 5, 2024, Snehal Patel, CEO and CFO of Greenwich LifeSciences, Inc., acquired 3,500 shares of the company's common stock.
- The purchase price was $12.49 per share.
- Following the transaction, Patel directly owns 5,343,777 shares of Greenwich LifeSciences.
- This Form 4/A is an amendment to a previous filing made on March 7, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of a stock purchase by the CEO. While insider buying can be seen as positive, it's a single transaction and doesn't provide strong evidence for a bullish outlook.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about their confidence in the company's future prospects.
Stakeholder Impact
- The stock purchase by the CEO could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/05/2024 | Date of stock purchase transaction |
| 03/07/2024 | Date of original Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.